CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.
CAR-NK cells
Combination therapy
Gastrointestinal cancers
Immunotherapy
Tumor microenvironment
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
14
07
2024
accepted:
08
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains a clinical challenge. Chimeric antigen receptor (CAR) natural killer (NK) cells have emerged as a promising alternative to CAR-T cells for immunotherapy of GI cancers. Notably, CAR-NK cells offer several advantages, including reduced risk of graft-versus-host disease, lower cytokine release syndrome, and the ability to target cancer cells through both CAR-dependent and natural cytotoxic mechanisms. This review comprehensively discusses the development and applications of CAR-NK cells in the treatment of GI cancers. We explored various sources of NK cells, CAR design strategies, and the current state of CAR-NK cell therapy for GI cancers, highlighting recent preclinical and clinical trials. Additionally, we addressed existing challenges and propose potential strategies to enhance the efficacy and safety of CAR-NK cell therapy. Our findings highlight the potential of CAR-NK cells to revolutionize GI cancer treatment and pave the way for future clinical applications.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains a clinical challenge. Chimeric antigen receptor (CAR) natural killer (NK) cells have emerged as a promising alternative to CAR-T cells for immunotherapy of GI cancers. Notably, CAR-NK cells offer several advantages, including reduced risk of graft-versus-host disease, lower cytokine release syndrome, and the ability to target cancer cells through both CAR-dependent and natural cytotoxic mechanisms.
MAIN BODY
METHODS
This review comprehensively discusses the development and applications of CAR-NK cells in the treatment of GI cancers. We explored various sources of NK cells, CAR design strategies, and the current state of CAR-NK cell therapy for GI cancers, highlighting recent preclinical and clinical trials. Additionally, we addressed existing challenges and propose potential strategies to enhance the efficacy and safety of CAR-NK cell therapy.
CONCLUSIONS
CONCLUSIONS
Our findings highlight the potential of CAR-NK cells to revolutionize GI cancer treatment and pave the way for future clinical applications.
Identifiants
pubmed: 39443938
doi: 10.1186/s12943-024-02151-3
pii: 10.1186/s12943-024-02151-3
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
237Informations de copyright
© 2024. The Author(s).
Références
Feng Z, Luan M, Zhu W, Xing Y, Ma X, Wang Y, et al. Targeted ferritinophagy in gastrointestinal cancer: from molecular mechanisms to implications. Arch Toxicol 2024;98(7):2007-18.
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, Bray F. Global burden of 5 major types of gastrointestinal Cancer. Gastroenterology. 2020;159(1):335–e349315.
pubmed: 32247694
doi: 10.1053/j.gastro.2020.02.068
Bordry N, Astaras C, Ongaro M, Goossens N, Frossard JL, Koessler T. Recent advances in gastrointestinal cancers. World J Gastroenterol. 2021;27(28):4493–503.
pubmed: 34366620
pmcid: 8326255
doi: 10.3748/wjg.v27.i28.4493
Rastin F, Javid H, Oryani MA, Rezagholinejad N, Afshari AR, Karimi-Shahri M. Immunotherapy for colorectal cancer: rational strategies and novel therapeutic progress. Int Immunopharmacol. 2024;126:111055.
pubmed: 37992445
doi: 10.1016/j.intimp.2023.111055
Javid H, Attarian F, Saadatmand T, Rezagholinejad N, Mehri A, Amiri H, Karimi-Shahri M. The therapeutic potential of immunotherapy in the treatment of breast cancer: rational strategies and recent progress. J Cell Biochem. 2023;124(4):477–94.
pubmed: 36966454
doi: 10.1002/jcb.30402
Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153.
pubmed: 35757715
pmcid: 9226391
doi: 10.3389/fimmu.2022.927153
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548–60.
pubmed: 31754328
pmcid: 6854376
doi: 10.7150/ijbs.34213
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99.
pubmed: 31900462
doi: 10.1038/s41573-019-0051-2
Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.
pubmed: 32853984
pmcid: 7452675
doi: 10.1016/j.ebiom.2020.102975
Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.
pubmed: 33933160
pmcid: 8088725
doi: 10.1186/s13045-021-01083-5
Dagher OK, Posey AD. Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24(12):1994–2007.
pubmed: 38012406
doi: 10.1038/s41590-023-01659-y
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097–100.
pubmed: 11896281
doi: 10.1126/science.1068440
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105(8):3051–7.
pubmed: 15632206
doi: 10.1182/blood-2004-07-2974
Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol. 2010;28(6):955–9.
pubmed: 20085940
pmcid: 2834435
doi: 10.1200/JCO.2009.24.4590
Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia. 1994;8(4):652–8.
pubmed: 8152260
Zhang J, Zheng H, Diao Y. Natural killer cells and current applications of chimeric Antigen receptor-modified NK-92 cells in Tumor Immunotherapy. Int J Mol Sci 2019, 20(2).
Klingemann H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023;25(5):451–7.
pubmed: 36610812
doi: 10.1016/j.jcyt.2022.12.003
Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23(2):330–8.
pubmed: 25373520
doi: 10.1038/mt.2014.219
Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020;10(1):2815.
pubmed: 32071339
pmcid: 7028910
doi: 10.1038/s41598-020-59736-3
Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–18.
pubmed: 31907401
doi: 10.1038/s41573-019-0052-1
Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–65.
pubmed: 19278419
pmcid: 2673358
doi: 10.1111/j.1365-2567.2008.03027.x
Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, et al. Larger size of Donor Alloreactive NK Cell Repertoire correlates with Better Response to NK Cell Immunotherapy in Elderly Acute myeloid leukemia patients. Clin Cancer Res. 2016;22(8):1914–21.
pubmed: 26787753
doi: 10.1158/1078-0432.CCR-15-1604
Pfefferle A, Huntington ND. You have got a fast CAR: chimeric Antigen receptor NK cells in Cancer Therapy. Cancers (Basel) 2020, 12(3).
Sarvaria A, Jawdat D, Madrigal JA, Saudemont A. Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Front Immunol. 2017;8:329.
pubmed: 28386260
pmcid: 5362597
doi: 10.3389/fimmu.2017.00329
Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017;31:37–54.
pubmed: 28838796
doi: 10.1016/j.smim.2017.07.009
Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE. 2011;6(6):e20740.
pubmed: 21698239
pmcid: 3116834
doi: 10.1371/journal.pone.0020740
Cany J, van der Waart AB, Spanholtz J, Tordoir M, Jansen JH, van der Voort R, et al. Combined IL-15 and IL-12 drives the generation of CD34(+)-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. Oncoimmunology. 2015;4(7):e1017701.
pubmed: 26140247
pmcid: 4485802
doi: 10.1080/2162402X.2015.1017701
Valamehr B, Robinson M, Abujarour R, Rezner B, Vranceanu F, Le T, et al. Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. Stem Cell Rep. 2014;2(3):366–81.
doi: 10.1016/j.stemcr.2014.01.014
Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells Engineered with chimeric Antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181–92. e185.
pubmed: 30082067
pmcid: 6084450
doi: 10.1016/j.stem.2018.06.002
Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. 2013;2(4):274–83.
pubmed: 23515118
pmcid: 3659832
doi: 10.5966/sctm.2012-0084
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5.
pubmed: 29567707
doi: 10.1126/science.aar6711
Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145–61.
pubmed: 33483715
pmcid: 8353572
doi: 10.1038/s41568-020-00323-z
Milone MC, Xu J, Chen SJ, Collins MA, Zhou J, Powell DJ Jr., Melenhorst JJ. Author correction: Engineering-enhanced CAR T cells for improved cancer therapy. Nat Cancer. 2021;2(10):1113.
pubmed: 35121886
doi: 10.1038/s43018-021-00277-7
Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S. Safarzadeh Kozani P. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10(1):24.
pubmed: 35468841
pmcid: 9036779
doi: 10.1186/s40364-022-00371-7
Gong L, Li Y, Cui K, Chen Y, Hong H, Li J, et al. Nanobody-Engineered Natural Killer Cell conjugates for Solid Tumor Adoptive Immunotherapy. Small. 2021;17(45):e2103463.
pubmed: 34761524
doi: 10.1002/smll.202103463
Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. 2015;6:195.
pubmed: 25972867
pmcid: 4412125
doi: 10.3389/fimmu.2015.00195
Yilmaz A, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13(1):168.
pubmed: 33287875
pmcid: 7720606
doi: 10.1186/s13045-020-00998-9
Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–98.
pubmed: 23550147
pmcid: 3667586
doi: 10.1158/2159-8290.CD-12-0548
Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370–83.
pubmed: 27000958
pmcid: 5529102
doi: 10.1038/nrclinonc.2016.36
Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016;30(3):157–67.
pubmed: 26574053
doi: 10.1016/j.blre.2015.10.003
Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–54.
pubmed: 25985798
doi: 10.1517/14712598.2015.1046430
Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697–706.
pubmed: 21742772
doi: 10.1158/0008-5472.CAN-11-0103
Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med. 2018;24(3):352–9.
pubmed: 29400710
pmcid: 5839992
doi: 10.1038/nm.4478
Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–31.
pubmed: 28725044
doi: 10.1038/leu.2017.226
Ruppel KE, Fricke S, Kohl U, Schmiedel D. Taking lessons from CAR-T cells and going Beyond: Tailoring Design and Signaling for CAR-NK cells in Cancer Therapy. Front Immunol. 2022;13:822298.
pubmed: 35371071
pmcid: 8971283
doi: 10.3389/fimmu.2022.822298
Tran AC, Zhang D, Byrn R, Roberts MR. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol. 1995;155(2):1000–9.
pubmed: 7608531
doi: 10.4049/jimmunol.155.2.1000
Topfer K, Cartellieri M, Michen S, Wiedemuth R, Muller N, Lindemann D, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201–12.
pubmed: 25740942
doi: 10.4049/jimmunol.1400330
Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73(6):1777–86.
pubmed: 23302231
doi: 10.1158/0008-5472.CAN-12-3558
Peng Y, Zhang W, Chen Y, Zhang L, Shen H, Wang Z, et al. Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma. Pharmacol Res. 2023;188:106656.
pubmed: 36640859
doi: 10.1016/j.phrs.2023.106656
Wang J, Lupo KB, Chambers AM, Matosevic S. Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggybac-engineered chimeric antigen receptor natural killer cells. J Immunother Cancer. 2018;6(1):136.
pubmed: 30514403
pmcid: 6278070
doi: 10.1186/s40425-018-0441-8
Majzner RG, Mackall CL. Tumor Antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–26.
pubmed: 30135176
doi: 10.1158/2159-8290.CD-18-0442
Cronk RJ, Zurko J, Shah NN. Bispecific Chimeric Antigen Receptor T cell therapy for B Cell malignancies and multiple myeloma. Cancers (Basel) 2020, 12(9).
Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568(7750):112–6.
pubmed: 30918399
pmcid: 6707377
doi: 10.1038/s41586-019-1054-1
Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022;28(10):2133–44.
pubmed: 36175679
pmcid: 9942695
doi: 10.1038/s41591-022-02003-x
Fu SJ, Qi CY, Xiao WK, Li SQ, Peng BG, Liang LJ. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection. Surgery. 2013;154(3):536–44.
pubmed: 23601901
doi: 10.1016/j.surg.2013.02.014
Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 2014;20(24):6418–28.
pubmed: 25320357
doi: 10.1158/1078-0432.CCR-14-1170
Yu M, Luo H, Fan M, Wu X, Shi B, Di S, et al. Development of GPC3-Specific chimeric Antigen receptor-Engineered Natural Killer cells for the Treatment of Hepatocellular Carcinoma. Mol Ther. 2018;26(2):366–78.
pubmed: 29339014
doi: 10.1016/j.ymthe.2017.12.012
Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, Sun B. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma. Immunology. 2023;169(2):204–18.
pubmed: 36640111
doi: 10.1111/imm.13624
Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20(1):70–5.
pubmed: 11753365
doi: 10.1038/nbt0102-70
Zhao J, Lin L, Luo Y, Cai Q, Jiang X, Liao C, Wei H. Optimization of GPC3-specific chimeric antigen receptor structure and its effect on killing hepatocellular carcinoma cells. Bioengineered. 2021;12(1):3674–83.
pubmed: 34261411
pmcid: 8806505
doi: 10.1080/21655979.2021.1950261
Fasolo A, Sessa C, Gianni L, Broggini M. Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. Ann Oncol. 2013;24(1):14–20.
pubmed: 23110808
doi: 10.1093/annonc/mds520
Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 2000;19(49):5582–9.
pubmed: 11114738
doi: 10.1038/sj.onc.1203859
Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67(3):1132–49.
pubmed: 28862760
doi: 10.1002/hep.29496
Huang X, Guo J, Li T, Jia L, Tang X, Zhu J, et al. c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo. J Biomed Res. 2021;36(1):10–21.
pubmed: 35403606
pmcid: 8894281
doi: 10.7555/JBR.35.20200207
Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44.
pubmed: 29568237
pmcid: 5859782
doi: 10.1186/s12935-018-0538-7
Liu B, Liu ZZ, Zhou ML, Lin JW, Chen XM, Li Z, et al. Development of c–MET–specific chimeric antigen receptor–engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Mol Med Rep. 2019;20(3):2823–31.
pubmed: 31524233
pmcid: 6691195
Hahn JN, Kaushik DK, Yong VW. The role of EMMPRIN in T cell biology and immunological diseases. J Leukoc Biol. 2015;98(1):33–48.
pubmed: 25977287
doi: 10.1189/jlb.3RU0215-045R
Peng F, Li H, You Q, Li H, Wu D, Jiang C et al. ,. CD147 as a Novel Prognostic Biomarker for Hepatocellular Carcinoma: A Meta-Analysis. Biomed Res Int 2017, 2017: 5019367.
Chen ZN, Mi L, Xu J, Song F, Zhang Q, Zhang Z, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006;65(2):435–44.
pubmed: 16690431
doi: 10.1016/j.ijrobp.2005.12.034
Tseng HC, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11(1):4810.
pubmed: 32968061
pmcid: 7511348
doi: 10.1038/s41467-020-18444-2
Wang Y, Zhao Y, Li M, Hou H, Jian Z, Li W, et al. Conversion of primary liver cancer after targeted therapy for liver cancer combined with AFP-targeted CAR T-cell therapy: a case report. Front Immunol. 2023;14:1180001.
pubmed: 37256142
pmcid: 10225497
doi: 10.3389/fimmu.2023.1180001
Yang C, You J, Pan Q, Tang Y, Cai L, Huang Y, et al. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral sleeping beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma. BMC Med. 2023;21(1):327.
pubmed: 37635247
pmcid: 10464109
doi: 10.1186/s12916-023-03016-0
Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, et al. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T cells. Cancer Immunol Res. 2019;7(11):1813–23.
pubmed: 31484657
doi: 10.1158/2326-6066.CIR-19-0026
Zhou L, Li Y, Zheng D, Zheng Y, Cui Y, Qin L, et al. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. Mol Ther Oncol. 2024;32(2):200817.
pubmed: 38882528
pmcid: 11179089
doi: 10.1016/j.omton.2024.200817
Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther. 2017;25(5):1248–58.
pubmed: 28366766
pmcid: 5417843
doi: 10.1016/j.ymthe.2017.03.010
Shiozawa M, Chang CH, Huang YC, Chen YC, Chi MS, Hao HC, et al. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells. BMC Immunol. 2018;19(1):27.
pubmed: 30075754
pmcid: 6091054
doi: 10.1186/s12865-018-0262-z
Hombach A, Koch D, Sircar R, Heuser C, Diehl V, Kruis W, et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther. 1999;6(2):300–4.
pubmed: 10435115
doi: 10.1038/sj.gt.3300813
Franzen AS, Boulifa A, Radecke C, Stintzing S, Raftery MJ, Pecher G. Next-generation CEA-CAR-NK-92 cells against solid tumors: overcoming Tumor Microenvironment challenges in Colorectal Cancer. Cancers (Basel) 2024, 16(2).
Li Y, Duo Y, Bao S, He L, Ling K, Luo J, et al. EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. Int J Nanomed. 2017;12:6239–57.
doi: 10.2147/IJN.S143293
Hao H, Zhen Y, Wang Z, Chen F, Xie X. A novel therapeutic drug for colon cancer: EpCAM Scfv-truncated protamine (tp)-siRNA. Cell Biol Int. 2013;37(8):860–4.
pubmed: 23576466
doi: 10.1002/cbin.10112
Liao MY, Lai JK, Kuo MY, Lu RM, Lin CW, Cheng PC, et al. An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer. Oncotarget. 2015;6(28):24947–68.
pubmed: 26317650
pmcid: 4694806
doi: 10.18632/oncotarget.4453
Zhang Q, Zhang H, Ding J, Liu H, Li H, Li H et al. ,. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models. J Immunol Res 2018, 2018: 4263520.
Schnalzger TE, de Groot MH, Zhang C, Mosa MH, Michels BE, Roder J et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. EMBO J 2019, 38(12).
Busse A, Asemissen AM, Nonnenmacher A, Braun F, Ochsenreither S, Stather D, et al. Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. Eur J Cancer. 2011;47(5):690–6.
pubmed: 21215610
doi: 10.1016/j.ejca.2010.11.021
Cabrera R, Ararat M, Xu Y, Brusko T, Wasserfall C, Atkinson MA, et al. Immune modulation of effector CD4 + and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2013;62(4):737–46.
pubmed: 23223899
doi: 10.1007/s00262-012-1380-8
Pahl J, Cerwenka A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology. 2017;222(1):11–20.
pubmed: 26264743
doi: 10.1016/j.imbio.2015.07.012
Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.
pubmed: 23833565
pmcid: 3700746
Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, et al. Exploiting natural killer group 2D receptors for CAR T-cell therapy. Future Oncol. 2017;13(18):1593–605.
pubmed: 28613086
doi: 10.2217/fon-2017-0102
Xiao L, Cen D, Gan H, Sun Y, Huang N, Xiong H, et al. Adoptive transfer of NKG2D CAR mRNA-Engineered Natural Killer cells in Colorectal Cancer patients. Mol Ther. 2019;27(6):1114–25.
pubmed: 30962163
pmcid: 6554529
doi: 10.1016/j.ymthe.2019.03.011
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.
pubmed: 17122771
doi: 10.1038/nature05384
Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1(4):389–402.
pubmed: 18371377
doi: 10.1016/j.stem.2007.08.001
Dai H, Tong C, Shi D, Chen M, Guo Y, Chen D, et al. Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial. Oncoimmunology. 2020;9(1):1846926.
pubmed: 33312759
pmcid: 7714531
doi: 10.1080/2162402X.2020.1846926
Wang Y, Chen M, Wu Z, Tong C, Dai H, Guo Y, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial. Oncoimmunology. 2018;7(7):e1440169.
pubmed: 29900044
pmcid: 5993480
doi: 10.1080/2162402X.2018.1440169
Wang X, Qiu W, Liu H, He M, He W, Li Z, et al. The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer. Cancer Biol Med. 2023;20(9):662–81.
pubmed: 37731205
pmcid: 10546094
Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S. Expansion of anti-mesothelin specific CD4 + and CD8 + T cell responses in patients with pancreatic carcinoma. PLoS ONE. 2014;9(2):e88133.
pubmed: 24520352
pmcid: 3919833
doi: 10.1371/journal.pone.0088133
Pastan I, Hassan R. Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014;74(11):2907–12.
pubmed: 24824231
pmcid: 4062095
doi: 10.1158/0008-5472.CAN-14-0337
Cao B, Liu M, Wang L, Liang B, Feng Y, Chen X, et al. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Biochem Biophys Res Commun. 2020;524(1):96–102.
pubmed: 31980173
doi: 10.1016/j.bbrc.2020.01.053
Batchu RB, Gruzdyn OV, Tavva PS, Kolli BK, Dachepalli R, Weaver DW, Gruber SA. Engraftment of mesothelin chimeric antigen receptor using a hybrid sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer. Surgery. 2019;166(4):503–8.
pubmed: 31416604
doi: 10.1016/j.surg.2019.05.047
Da Y, Liu Y, Hu Y, Liu W, Ma J, Lu N, et al. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. Oncoimmunology. 2022;11(1):2054105.
pubmed: 35371622
pmcid: 8967397
doi: 10.1080/2162402X.2022.2054105
Legg JA, Herbert JM, Clissold P, Bicknell R. Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis. 2008;11(1):13–21.
pubmed: 18264786
doi: 10.1007/s10456-008-9100-x
Kidd T, Brose K, Mitchell KJ, Fetter RD, Tessier-Lavigne M, Goodman CS, Tear G. Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors. Cell. 1998;92(2):205–15.
pubmed: 9458045
doi: 10.1016/S0092-8674(00)80915-0
Prasad A, Qamri Z, Wu J, Ganju RK. Slit-2/Robo-1 modulates the CXCL12/CXCR4-induced chemotaxis of T cells. J Leukoc Biol. 2007;82(3):465–76.
pubmed: 17565045
doi: 10.1189/jlb.1106678
He H, Di Y, Liang M, Yang F, Yao L, Hao S, et al. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. Oncol Rep. 2013;30(2):651–8.
pubmed: 23733161
doi: 10.3892/or.2013.2516
Qu Y, Bi JZ. [Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells]. Zhonghua Yi Xue Za Zhi. 2018;98(11):860–6.
pubmed: 29609271
Xia N, Haopeng P, Gong JU, Lu J, Chen Z, Zheng Y, et al. Robo1-specific CAR-NK Immunotherapy enhances efficacy of (125)I seed brachytherapy in an Orthotopic Mouse Model of Human pancreatic carcinoma. Anticancer Res. 2019;39(11):5919–25.
pubmed: 31704816
doi: 10.21873/anticanres.13796
Lee YE, Ju A, Choi HW, Kim JC, Kim EE, Kim TS, et al. Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment. J Control Release. 2020;326:310–23.
pubmed: 32682905
doi: 10.1016/j.jconrel.2020.07.016
Li E, Liu L, Li F, Luo L, Zhao S, Wang J, et al. PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc. Prostate. 2017;77(16):1563–72.
pubmed: 28971496
doi: 10.1002/pros.23432
Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19(10):1288–96.
pubmed: 10713670
doi: 10.1038/sj.onc.1203426
Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005;31(2):119–25.
pubmed: 16024997
doi: 10.1097/01.mpa.0000173459.81193.4d
Teng KY, Mansour AG, Zhu Z, Li Z, Tian L, Ma S, et al. Off-the-Shelf prostate Stem Cell Antigen-Directed chimeric Antigen receptor Natural Killer Cell Therapy to treat pancreatic Cancer. Gastroenterology. 2022;162(4):1319–33.
pubmed: 34999097
doi: 10.1053/j.gastro.2021.12.281
Guo D, Jin C, Gao Y, Lin H, Zhang L, Zhou Y, et al. GPR116 receptor regulates the antitumor function of NK cells via Galphaq/HIF1alpha/NF-kappaB signaling pathway as a potential immune checkpoint. Cell Biosci. 2023;13(1):51.
pubmed: 36895027
pmcid: 9999509
doi: 10.1186/s13578-023-01005-7
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341–54.
pubmed: 15864276
doi: 10.1038/nrc1609
Wu X, Huang S. HER2-specific chimeric antigen receptor-engineered natural killer cells combined with apatinib for the treatment of gastric cancer. Bull Cancer. 2019;106(11):946–58.
pubmed: 31711572
doi: 10.1016/j.bulcan.2019.03.012
Cao B, Liu M, Huang J, Zhou J, Li J, Lian H, et al. Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer. Int J Biol Sci. 2021;17(14):3850–61.
pubmed: 34671203
pmcid: 8495380
doi: 10.7150/ijbs.64630
Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, et al. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the treatment of gastric Cancer. J Natl Cancer Inst. 2019;111(4):409–18.
pubmed: 30203099
doi: 10.1093/jnci/djy134
Kang CH, Kim Y, Lee DY, Choi SU, Lee HK, Park CH. c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer. Cancers (Basel) 2021, 13(22).
Kim M, Pyo S, Kang CH, Lee CO, Lee HK, Choi SU, Park CH. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS ONE. 2018;13(6):e0198347.
pubmed: 29874279
pmcid: 5991383
doi: 10.1371/journal.pone.0198347
Jung M, Yang Y, McCloskey JE, Zaman M, Vedvyas Y, Zhang X, et al. Chimeric Antigen Receptor T Cell therapy targeting ICAM-1 in gastric Cancer. Mol Ther Oncolytics. 2020;18:587–601.
pubmed: 32995483
pmcid: 7501410
doi: 10.1016/j.omto.2020.08.009
Wu D, Lv J, Zhao R, Wu Z, Zheng D, Shi J, et al. PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomark Res. 2020;8:3.
pubmed: 32010446
pmcid: 6988264
doi: 10.1186/s40364-020-0183-x
Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med. 2024;30(8):2224–34.
Liu T, Dai X, Xu Y, Guan T, Hong L, Zaib T, et al. CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma. J Transl Med. 2023;21(1):710.
pubmed: 37817249
pmcid: 10563326
doi: 10.1186/s12967-023-04409-8
Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin Cancer Res. 2016;22(14):3425–31.
pubmed: 27208063
pmcid: 4947428
doi: 10.1158/1078-0432.CCR-15-2428
Xuan Y, Sheng Y, Zhang D, Zhang K, Zhang Z, Ping Y, et al. Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models. Transl Oncol. 2021;14(8):101138.
pubmed: 34052626
pmcid: 8176370
doi: 10.1016/j.tranon.2021.101138
Lin X, Guan T, Xu Y, Li Y, Lin Y, Chen S, et al. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma. Front Immunol. 2024;15:1337489.
pubmed: 38566988
pmcid: 10985341
doi: 10.3389/fimmu.2024.1337489
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53.
pubmed: 32023374
pmcid: 7101242
doi: 10.1056/NEJMoa1910607
Honikel MM, Olejniczak SH. Co-stimulatory receptor signaling in CAR-T cells. Biomolecules 2022, 12(9).
Kong JC, Sa’ad MA, Vijayan HM, Ravichandran M, Balakrishnan V, Tham SK, Tye GJ. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges. Front Immunol. 2024;15:1384039.
pubmed: 38726000
pmcid: 11079817
doi: 10.3389/fimmu.2024.1384039
Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G et al. ,. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. J Immunol Res 2020, 2020: 1924379.
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.
pubmed: 33824268
pmcid: 8024391
doi: 10.1038/s41408-021-00459-7
Wang YA, Ranti D, Bieber C, Galsky M, Bhardwaj N, Sfakianos JP, Horowitz A. NK Cell-targeted immunotherapies in bladder Cancer: beyond checkpoint inhibitors. Bladder Cancer. 2023;9(2):125–39.
pubmed: 38993289
pmcid: 11181717
doi: 10.3233/BLC-220109
Ramakrishna S, Barsan V, Mackall C. Prospects and challenges for use of CAR T cell therapies in solid tumors. Expert Opin Biol Ther. 2020;20(5):503–16.
pubmed: 32125191
doi: 10.1080/14712598.2020.1738378
Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I. The hypoxic tumour microenvironment. Oncogenesis. 2018;7(1):10.
pubmed: 29362402
pmcid: 5833859
doi: 10.1038/s41389-017-0011-9
Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, et al. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022;139(26):3708–21.
pubmed: 35090171
pmcid: 11290597
doi: 10.1182/blood.2021012811
Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol. 2023;14:1166038.
pubmed: 37205115
pmcid: 10187144
doi: 10.3389/fimmu.2023.1166038
Riggan L, Shah S, O’Sullivan TE. Arrested development: suppression of NK cell function in the tumor microenvironment. Clin Transl Immunol. 2021;10(1):e1238.
doi: 10.1002/cti2.1238
Daher M, Rezvani K. Outlook for New CAR-Based therapies with a focus on CAR NK cells: what lies Beyond CAR-Engineered T cells in the race against Cancer. Cancer Discov. 2021;11(1):45–58.
pubmed: 33277313
doi: 10.1158/2159-8290.CD-20-0556
Rouce RH, Shaim H, Sekine T, Weber G, Ballard B, Ku S, et al. The TGF-beta/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016;30(4):800–11.
pubmed: 26621337
doi: 10.1038/leu.2015.327
Sun H, Sun C. The rise of NK Cell checkpoints as Promising therapeutic targets in Cancer Immunotherapy. Front Immunol. 2019;10:2354.
pubmed: 31681269
pmcid: 6812684
doi: 10.3389/fimmu.2019.02354
Urena-Bailen G, Dobrowolski JM, Hou Y, Dirlam A, Roig-Merino A, Schleicher S et al. Preclinical evaluation of CRISPR-Edited CAR-NK-92 cells for off-the-Shelf treatment of AML and B-ALL. Int J Mol Sci 2022, 23(21).
Yang K, Zhao Y, Sun G, Zhang X, Cao J, Shao M, et al. Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy. Front Immunol. 2022;13:1081546.
pubmed: 36741400
doi: 10.3389/fimmu.2022.1081546
Li M, Zhi L, Yin M, Guo C, Zhang H, Lu C, Zhu W. A novel bispecific chimeric PD1-DAP10/NKG2D receptor augments NK92-cell therapy efficacy for human gastric cancer SGC-7901 cell. Biochem Biophys Res Commun. 2020;523(3):745–52.
pubmed: 31952789
doi: 10.1016/j.bbrc.2020.01.005
Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633–40.
pubmed: 11698225
doi: 10.1016/S1471-4906(01)02060-9
Siegler EL, Zhu Y, Wang P, Yang L. Off-the-Shelf CAR-NK cells for Cancer Immunotherapy. Cell Stem Cell. 2018;23(2):160–1.
pubmed: 30075127
doi: 10.1016/j.stem.2018.07.007
Van den Eynde A, Gehrcken L, Verhezen T, Lau HW, Hermans C, Lambrechts H, et al. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J Hematol Oncol. 2024;17(1):8.
pubmed: 38331849
pmcid: 10854128
doi: 10.1186/s13045-024-01525-w
Ouyang W, Jin SW, Xu N, Liu WY, Zhao H, Zhang L et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer 2024, 12(4).
Bailey SR, Maus MV. Gene editing for immune cell therapies. Nat Biotechnol. 2019;37(12):1425–34.
pubmed: 31160723
doi: 10.1038/s41587-019-0137-8
Li J, Hu H, Lian K, Zhang D, Hu P, He Z, et al. CAR-NK cells in combination therapy against cancer: a potential paradigm. Heliyon. 2024;10(5):e27196.
pubmed: 38486782
pmcid: 10937699
doi: 10.1016/j.heliyon.2024.e27196
Tao K, He M, Tao F, Xu G, Ye M, Zheng Y, Li Y. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemother Pharmacol. 2018;82(5):815–27.
pubmed: 30132099
doi: 10.1007/s00280-018-3670-0
Klapdor R, Wang S, Hacker U, Buning H, Morgan M, Dork T, et al. Improved killing of Ovarian Cancer Stem cells by combining a novel chimeric Antigen receptor-based immunotherapy and chemotherapy. Hum Gene Ther. 2017;28(10):886–96.
pubmed: 28836469
doi: 10.1089/hum.2017.168
Klapdor R, Wang S, Morgan MA, Zimmermann K, Hachenberg J, Buning H et al. ,. NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44. Biomedicines 2021, 9(10).
Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-Based CAR T cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Res. 2018;78(4):1031–43.
pubmed: 29222400
doi: 10.1158/0008-5472.CAN-17-1788
Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, et al. Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on Tumor response in patients with Advanced Non-small Cell Lung Cancer: results of the PEMBRO-RT phase 2 Randomized Clinical Trial. JAMA Oncol. 2019;5(9):1276–82.
pubmed: 31294749
pmcid: 6624814
doi: 10.1001/jamaoncol.2019.1478
Xie G, Gu D, Zhang L, Chen S, Wu D. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. Cancer Biol Ther. 2017;18(8):547–51.
pubmed: 28665741
pmcid: 5652971
doi: 10.1080/15384047.2017.1345389
Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516–24.
pubmed: 26951040
pmcid: 6053911
doi: 10.1038/nrclinonc.2016.30
Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436(7054):1186–90.
pubmed: 15995699
pmcid: 1352168
doi: 10.1038/nature03884
Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol Rev. 2006;214:130–42.
pubmed: 17100881
doi: 10.1111/j.1600-065X.2006.00460.x
Rastin F, Oryani MA, Iranpour S, Javid H, Hashemzadeh A, Karimi-Shahri M. A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery. J Mater Chem B. 2024;12(4):872–94.
pubmed: 38193564
doi: 10.1039/D3TB02471G
Patel AA. Recent advances in immunotherapy in cancer treatment. Cell Mol Biol (Noisy-le-grand). 2024;70(5):89–99.
pubmed: 38814230
doi: 10.14715/cmb/2024.70.5.13
Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–44.
pubmed: 27454297
pmcid: 4966328
doi: 10.1172/JCI83092
John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology. 2013;2(10):e26286.
pubmed: 24353912
pmcid: 3862687
doi: 10.4161/onci.26286
Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039–41.
pubmed: 28031179
pmcid: 5391777
doi: 10.1182/blood-2016-09-738245
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6(1):38.
pubmed: 32382051
pmcid: 9728094
doi: 10.1038/s41572-020-0160-6
Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341–55.
pubmed: 27145284
pmcid: 5085160
doi: 10.18632/oncotarget.9114
Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–56.
pubmed: 30102295
pmcid: 6126939
doi: 10.1038/nbt.4195
Li J, Hu H, Lian H, Yang S, Liu M, He J, et al. NK-92MI cells Engineered with anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer. Int J Biol Sci. 2024;20(5):1578–601.
pubmed: 38481806
pmcid: 10929190
doi: 10.7150/ijbs.88539
Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.
pubmed: 28389661
pmcid: 5428439
doi: 10.1038/s41598-017-00462-8
Lanuza PM, Pesini C, Arias MA, Calvo C, Ramirez-Labrada A, Pardo J. Recalling the Biological significance of Immune checkpoints on NK cells: a chance to overcome LAG3, PD1, and CTLA4 inhibitory pathways by adoptive NK cell transfer? Front Immunol. 2019;10:3010.
pubmed: 31998304
doi: 10.3389/fimmu.2019.03010
Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–68.
pubmed: 30198904
pmcid: 6159991
doi: 10.1172/JCI99317
Pang Z, Wang Z, Li F, Feng C, Mu X. Current progress of CAR-NK Therapy in Cancer Treatment. Cancers (Basel) 2022, 14(17).
Zhang L, Liu M, Yang S, Wang J, Feng X, Han Z. Natural killer cells: of-the-shelf cytotherapy for cancer immunosurveillance. Am J Cancer Res. 2021;11(4):1770–91.
pubmed: 33948388
pmcid: 8085843
Egli L, Kaulfuss M, Mietz J, Picozzi A, Verhoeyen E, Munz C, Chijioke O. CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison. Exp Hematol Oncol. 2024;13(1):51.
pubmed: 38745250
pmcid: 11092129
doi: 10.1186/s40164-024-00522-6